X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-24 | GOSS | Aranda Richard | Chief Medical Officer | S - Sale | $0.66 | -1,908 | 199,430 | -1% | -$1,260 | ||||||
2024-06-21 | GOSS | Hasnain Faheem | Pres, CEO | P - Purchase | $0.67 | +372,000 | 5,528,366 | +7% | +$250,282 | ||||||
2024-06-18 | GOSS | Giraudo Bryan | COO, CFO | P - Purchase | $0.59 | +100,000 | 480,010 | +26% | +$59,110 | ||||||
2024-06-17 | GOSS | Smith Robert Paul Jr | Chief Commercial Officer | P - Purchase | $0.60 | +25,000 | 25,000 | New | +$15,050 | ||||||
2024-03-27 | GOSS | Christian Waage | EVP, Tech Ops, Admin | S - Sale | $1.16 | -6,430 | 654,048 | -1% | -$7,430 | ||||||
2024-03-27 | GOSS | Giraudo Bryan | COO, CFO | S - Sale | $1.16 | -6,430 | 472,747 | -1% | -$7,431 | ||||||
2024-03-27 | GOSS | Hasnain Faheem | Pres, CEO | S - Sale | $1.16 | -23,172 | 5,156,366 | 0% | -$26,773 | ||||||
2024-03-18 | GOSS | Aranda Richard | Chief Medical Officer | S - Sale | $1.33 | -4,018 | 198,799 | -2% | -$5,342 | ||||||
2024-03-18 | GOSS | Peterson Caryn | EVP, Regulatory Affairs | S - Sale | $1.33 | -4,018 | 49,833 | -7% | -$5,343 | ||||||
2023-11-15 | GOSS | Milligan Sandra | Dir | P - Purchase | $0.79 | +32,000 | 32,000 | New | +$25,213 | ||||||
2023-11-13 | GOSS | Giraudo Bryan | COO, CFO | P - Purchase | $0.56 | +200,000 | 479,177 | +72% | +$112,880 | ||||||
2023-06-22 | GOSS | Aranda Richard | Chief Medical Officer | S - Sale | $1.29 | -1,814 | 200,113 | -1% | -$2,340 | ||||||
2023-04-04 | GOSS | Giraudo Bryan | COO, CFO | P - Purchase | $1.02 | +55,000 | 225,157 | +32% | +$56,095 | ||||||
| D | 2023-03-20 | GOSS | Christian Waage | EVP, Tech Ops, Admin | P - Purchase | $1.20 | +18,500 | 637,088 | +3% | +$22,145 | |||||
| D | 2023-03-20 | GOSS | Giraudo Bryan | COO, CFO | P - Purchase | $0.97 | +50,000 | 170,157 | +42% | +$48,435 | |||||
| DM | 2023-03-20 | GOSS | Hasnain Faheem | Pres, CEO | P - Purchase | $1.14 | +878,572 | 4,639,362 | +23% | +$1,000,389 | |||||
2023-03-16 | GOSS | Carter Laura | Chief Scientific Officer | S - Sale | $1.10 | -6,029 | 76,263 | -7% | -$6,620 | ||||||
2023-03-16 | GOSS | Aranda Richard | Chief Medical Officer | S - Sale | $1.10 | -7,563 | 201,927 | -4% | -$8,304 | ||||||
2023-03-16 | GOSS | Peterson Caryn | EVP, Regulatory Affairs | S - Sale | $1.10 | -7,564 | 53,851 | -12% | -$8,305 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |